The combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 290-301

  Fondello, Chiara ^a   Agnetti, Lucrecia ^a   Villaverde, Marcela S ^a   Simian, Marina ^b   Glikin, Gerardo C ^a   Finocchiaro, Liliana M E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

Author keywords

Bleomycin; HSV thymidine kinase; Interferon ; Melanoma; Spheroids

Indexed keywords

BETA INTERFERON; BLEOMYCIN; HUMAN INTERFERON; MELAN A; MELANOCYTE PROTEIN PMEL 17; VIRUS VECTOR; REACTIVE OXYGEN METABOLITE; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BETA INTERFERON GENE; CANCER GENE THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; SUICIDE GENE; WILD TYPE; CANCER STEM CELL; CELL CLONE; CELL CYCLE; CELL DEATH; CELL SHAPE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SKIN NEOPLASMS; SUICIDE TRANSGENE; TUMOR CELL LINE;

BIOMARKERS, TUMOR; BLEOMYCIN; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; CLONE CELLS; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; MELANOMA; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS; SPHEROIDS, CELLULAR;

EID: 84978951865     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.06.038     Document Type: Article

References (46)

1. [1] Siegel, R., Miller, K., Jemal, A., Cancer statistics. CA Cancer J. Clin. 65 (2015), 5–29.
2. [2] Tarhini, A.A., Agarwala, S.S., Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther. 19 (2006), 19–25.
3. [3] Chin, L., Garraway, L.A., Fisher, D.E., Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20 (2006), 2149–2182.
4. [4] Flaherty, K.T., BRAF inhibitors and melanoma. Cancer J. 17 (2011), 505–511.
5. [5] Girotti, M.R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., Suijkerbuijk, B.M., Menard, D., McLeary, R., Johnson, L., Fish, L., Ejiama, S., Sanchez-Laorden, B., Hohloch, J., Carragher, N., Macleod, K., Ashton, G., Marusiak, A.A., Fusi, A., Brognard, J., Frame, M., Lorigan, P., Marais, R., Springer, C., Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27 (2015), 85–96.
6. [6] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbé, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
7. [7] Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G.P., Daniels, G.A., Harrington, K., Middleton, M.R., Miller, W.H. Jr., Zager, J.S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., Coffin, R.S., Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33 (2015), 2780–2788.
8. [8] Ossowski, L., Aguirre-Ghiso, J.A., Dormancy of metastatic melanoma. Pigm. Cell Melanoma Res. 23 (2010), 41–56.
9. [9] Paez, D., Labonte, M.J., Bohanes, P., Zhang, W., Benhanim, L., Ning, Y., Wakatsuki, T., Loupakis, F., Lenz, H.J., Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin. Cancer Res. 18 (2011), 645–653.
10. [10] Alison, M.R., Lin, W.R., Lim, S.M.L., Nicholson, L.J., Cancer stem cells: in the line of fire. Cancer Treat. Rev. 38 (2012), 589–598.
11. [11] Sato, A., Okada, M., Shibuya, K., Watanabe, E., Seino, S., Narita, Y., Shibui, S., Kayama, T., Kitanaka, C., Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res. 12 (2014), 119–131.
12. [12] Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., Morrison, S.J., Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
13. [13] Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson, T.M., Morrison, S.J., Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18 (2010), 510–523.
14. [14] Hendrix, M.J.C., Seftor, E.A., Hess, A.R., Seftor, R.E.B., Molecular plasticity of human melanoma cells. Oncogene 22 (2003), 3070–3075.
15. [15] Somasundaram, R., Villanueva, J., Herlyn, M., Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv. Pharmacol. 65 (2012), 335–359.
16. [16] Klatzmann, D., Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene to be followed by ganciclovir administration. Hum. Gene Ther. 7 (1996), 255–267.
17. [17] Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L., Abraham, G.N., The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 (1993), 5274–5283.
18. [18] Villaverde, M.S., Gil-Cardeza, M.L., Glikin, G.C., Finocchiaro, L.M., Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells. Cancer Gene Ther. 19 (2012), 420–430.
19. [19] Rossi, U.A., Gil-Cardeza, M.L., Villaverde, M.S., Finocchiaro, L.M., Glikin, G.C., Interferon-β gene transfer induces a strong cytotoxic bystander effect on melanoma cells. Biomed. Pharmacother. 72 (2015), 44–51.
20. [20] Atzpodien, J., Neuber, K., Kamanabrou, D., Fluck, M., Brocker, E.B., Neumann, C., Rünger, T.M., Schuler, G., von den Driesch, P., Müller, I., Paul, E., Patzelt, T., Reitz, M., Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer 86 (2002), 179–184.
21. [21] Finocchiaro, L.M.E., Fondello, C., Gil-Cardeza, M.L., Rossi, U.A., Villaverde, M.S., Riveros, M.D., Glikin, G.C., Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Hum. Gene Ther. 26 (2015), 367–376.
22. [22] Jingyang, C., Stubbe, J., Bleomycins: towards better therapeutics. Nat. Rev. Can. 5 (2005), 102–112.
23. [23] Lau, K.G., Hattori, Y., Chopra, S., O'Toole, E.A., Storey, A., Nagai, T., Maitani, Y., Ultra-deformable liposomes containing bleomycin: in vitro stability and toxicity on human cutaneous keratinocyte cell lines. Int. J. Pharm. 300 (2005), 4–12.
24. [24] Mima, H., Yamamoto, S., Ito, M., Tomoshige, R., Tabata, Y., Tamai, K., Kaneda, Y., Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol. Cancer Ther. 5 (2006), 1021–1028.
25. [25] Gil-Cardeza, M.L., Rossi, U.A., Villaverde, M.S., Glikin, G.C., Finocchiaro, L.M.E., Cationic lipid:DNA complexes allow bleomycin uptake in canine melanoma cells. Biomed. Pharmacother. 67 (2013), 269–275.
26. [26] Nowak, A.K., Robinson, B.W., Lake, R.A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63 (2003), 4490–4496.
27. [27] Ramakrishnan, R., Antonia, S., Gabrilovich, D.I., Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol. Immunother. 57 (2008), 1523–1529.
28. [28] Fridlender, Z.G., Sun, J., Singhal, S., Kapoor, V., Cheng, G., Suzuki, E., Albelda, S.M., Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol. Ther. 18 (2010), 1947–1959.
29. [29] Gil-Cardeza, M.L., Villaverde, M.S., Fiszman, G.L., Altamirano, N.A., Cwirenbaum, R.A., Glikin, G.C., Finocchiaro, L.M.E., Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Ther. 17 (2010), 26–36.
30. [30] Raffo, D., Berardi, D.E., Pontiggia, O., Todaro, L., de Kier Joffé, E.B., Simian, M., Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res. Treat. 142 (2013), 537–548.
31. [31] Hoek, K.S., Schlegel, N.C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B.L., Nathanson, K.L., Phillips, D.J., Herlyn, M., Schadendorf, D., Dummer, R., Metastatic potential of melanomas defined by specifi c gene expression profiles with no BRAF signature. Pigment Cell Res. 19 (2006), 290–302.
32. [32] Dissanayake, S.K., Olkhanud, P.B., O'Connell, M.P., Carter, A., French, A.D., Camilli, T.C., Emeche, C.D., Hewitt, K.J., Rosenthal, D.T., Leotlela, P.D., Wade, M.S., Yang, S.W., Brant, L., Nickoloff, B.J., Messina, J.L., Biragyn, A., Hoek, K.S., Taub, D.D., Longo, D.L., Sondak, V.K., Hewitt, S.M., Weeraratna, A.T., Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 68 (2008), 10205–10214.
33. [33] Finocchiaro, L.M.E., Glikin, G.C., Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Ther. 19 (2012), 852–861.
34. [34] Gupta, S.C., Hevia, D., Patchva, S., Park, B., Koh, W., Aggarwal, B.B., Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 16 (2012), 1295–1322.
35. [35] Chang, C.W., Chen, Y.S., Chou, S.H., Han, C.L., Chen, Y.J., Yang, C.C., Huang, C.Y., Lo, J.F., Distinct subpopulations of head and neck cancer cells with different levels of intracellular reactive oxygen species exhibit diverse stemness, proliferation, and chemosensitivity. Cancer Res. 74 (2014), 6291–6305.
36. [36] Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., Qian, D., Lam, J.S., Ailles, L.E., Wong, M., Joshua, B., Kaplan, M.J., Wapnir, I., Dirbas, F.M., Somlo, G., Garberoglio, C., Paz, B., Shen, J., Lau, S.K., Quake, S.R., Brown, J.M., Weissman, I.L., Clarke, M.F., Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (2009), 780–783.
37. [37] Shi, X., Zhang, Y., Zheng, J., Pan, J., Reactive oxygen species in cancer stem cells. Antioxid. Redox Signal. 16 (2012), 1215–1228.
38. [38] Mahller, Y.Y., Williams, J.P., Baird, W.H., Mitton, B., Grossheim, J., Saeki, Y., Cancelas, J.A., Ratner, N., Cripe, T.P., Neuro blastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One, 4, 2009, e4235.
39. [39] Davies, M.A., Samuels, Y., Analysis of the genome to personalize therapy for melanoma. Oncogene 29 (2010), 5545–5555.
40. [40] Tesio, M., Trumpp, A., Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell 9 (2011), 187–192.
41. [41] Cheung, T.H., Rando, T.A., Molecular regulation of stem cell quiescence. Nat. Rev. Mol. Cell Biol. 14 (2013), 329–340.
42. [42] Jang, Y.Y., Sharkis, S.J., A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110 (2007), 3056–3063.
43. [43] Yoneyama, M., Kawada, K., Gotoh, Y., Shiba, T., Ogita, K., Endogenous reactive oxygen species are essential for proliferation of neural stem/progenitor cells. Neurochem. Int. 56 (2010), 740–746.
44. [44] Rejman, J., Bragonzi, A., Conese, M., Role of clathrin- and caveolea-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 12 (2005), 468–474.
45. [45] Resina, S., Prevot, P., Thierry, A.R., Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy. PLoS One, 4, 2009, e6058.
46. [46] Schatton, T., Murphy, G.F., Frank, N.Y., Yamaura, K., Waaga-Gasser, A.M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L.M., Weishaupt, C., Fuhlbrigge, R.C., Kupper, T.S., Sayegh, M.H., Frank, M.H., Identification of cells initiating human melanomas. Nature 451 (2008), 345–349.